Medical and Pharmaceutical Against the rise of early onset cancer: a Mugglehead roundup Cancer treatment markets are set to expand rapidly over the next decade Joseph Morton4 hours ago
Medical and Pharmaceutical Lucid Diagnostics joins Russell 2000 and 3000 indexes Investment managers and institutional investors widely use the Russell indexes for both index funds and active investment benchmarks Joseph Morton2 days ago
Medical and Pharmaceutical Phase Scientific International advances urine biopsy tech with $34M fundraising round The company has gained strong market traction by launching over 30 diagnostic products across multiple health categories Joseph Morton3 days ago
Medical and Pharmaceutical Prenetics Global shares spike on significant revenue developments The company projects 2025 revenue to range between USD$73 million and USD$85 million Joseph MortonMay 22, 2025
Medical and Pharmaceutical BioMark Diagnostics reveals AI breakthrough in early lung cancer detection The model uses graph neural networks to interpret complex biological interactions Joseph MortonMay 20, 2025
AI and Autonomy Canadian healthcare just got a little more organized with Oracle AI Oracle's agent combines generative AI, agentic technology, automation, multimodal voice, and screen-driven assistance into one solution Joseph MortonMay 15, 2025
Medical and Pharmaceutical Breath tests could soon become key diagnosis tool for multiple diseases Researchers are working to bring this technology to market Joseph MortonMay 14, 2025
Medical and Pharmaceutical International lung cancer screening market poised for steady growth: 2025 report It will be worth over US$1.3 billion more than its current valuation by 2029, The Business Research Company says Rowan DunneMay 9, 2025
Medical and Pharmaceutical Breath Diagnostics gives the public the chance to join the fight against cancer Regulation crowdfunding allows a startup or private company to reach out directly to the public for support Joseph MortonMay 7, 2025
Medical and Pharmaceutical Breath Diagnostics now offering a compelling investment opportunity The lung cancer breath test developer is enabling investors to buy US$3 shares through a Reg CF financing Rowan DunneMay 7, 2025